

Short-Acting Colony Stimulating Factors: Part B Coverage

Effective: January 1, 2018

Covered Products

- Granix (tbo-filgrastim)
- Nivestym (filgrastim-aafi)
- Neupogen (filgrastim)
- Zarxio (filgrastim-sndz)

Coverage Details	
Covered Uses	All FDA-approved indications and indications per the Local Coverage Determinations (LCDs) and National Coverage Determinations (NCDs)
Exclusion Criteria	None
Additional Coverage Information	Tufts Health Plan recommends the use of Zarxio (filgrastim-sndz) as the most cost effective short-acting colony stimulating factor.